CRISPR Therapeutics AG (CRSP) concluded trading on Wednesday at a closing price of $44.20, with 5.37 million shares of worth about $237.31 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.41% during that period and on January 22, 2025 the price saw a gain of about 6.48%. Currently the company’s common shares owned by public are about 85.34M shares, out of which, 81.68M shares are available for trading.
Stock saw a price change of 15.22% in past 5 days and over the past one month there was a price change of 7.65%. Year-to-date (YTD), CRSP shares are showing a performance of 12.30% which decreased to -28.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $36.52 but also hit the highest price of $91.10 during that period. The average intraday trading volume for CRISPR Therapeutics AG shares is 1.81 million. The stock is currently trading 8.89% above its 20-day simple moving average (SMA20), while that difference is down -2.53% for SMA50 and it goes to -13.17% lower than SMA200.
CRISPR Therapeutics AG (NASDAQ: CRSP) currently have 85.34M outstanding shares and institutions hold larger chunk of about 69.43% of that.
The stock has a current market capitalization of $3.77B and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$2.82 in the same period. It has Quick Ratio of 21.64 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRSP, volatility over the week remained 5.23% while standing at 4.58% over the month.
Analysts are in expectations that CRISPR Therapeutics AG (CRSP) stock would likely to be making an EPS of -1.18 in the current quarter, while forecast for next quarter EPS is -1.38 and it is -5.04 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.93 which is -0.74 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 1.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -166.62% while it is estimated to increase by 3.01% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on August 06, 2024 offering a Buy rating for the stock and assigned a target price range of between $88 and $84 to it. Coverage by Rodman & Renshaw stated CRISPR Therapeutics AG (CRSP) stock as a Buy in their note to investors on August 02, 2024, suggesting a price target of $90 for the stock. Stock get an Underperform rating from TD Cowen on December 11, 2023.
